{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:48:57Z","timestamp":1793317737060,"version":"4.5.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"18","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422053"],"award-info":[{"award-number":["82422053"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173037"],"award-info":[{"award-number":["82173037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230097"],"award-info":[{"award-number":["82230097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273128"],"award-info":[{"award-number":["82273128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3404104"],"award-info":[{"award-number":["2023YFC3404104"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Defects in homologous recombination repair (HR) make cells highly susceptible to PARP inhibitors. However, the limited efficacy of PARP inhibitors in targeting HR wild-type tumors restricts their broad utility in cancer treatment. Clinical trials of PARP inhibitors have revealed greater efficacy in men with metastatic castration-resistant prostate cancer harboring BRCA2 mutations compared with those with mutations in other HR genes. To address this, we developed a peptide-based proteolysis-targeting chimera (PROTAC) drug that specifically targets BRCA2, leading to its degradation in a DDB1-dependent manner. The interaction between DDB1 and BRCA2 facilitated nuclear accumulation of the BRCA2 peptide PROTAC (BPD), thereby promoting BRCA2 degradation in response to DNA damage. Combining BPD treatment with PARP inhibitors promoted cell death in prostate cancer cells and induced tumor regression in animal models. These findings suggest that the development of a PROTAC drug targeting BRCA2 offers a promising strategy in combination with PARP inhibitor therapy for treating cancers without HR defects. This approach holds potential for expanding the therapeutic application of PARP inhibition for prostate cancer management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>BPD is a peptide-based PROTAC that effectively degrades BRCA2, selectively accumulates in tumor cells, reduces homologous recombination efficiency, and enhances sensitivity to PARP inhibitors in prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-24-4096","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:14:32Z","timestamp":1753812872000},"page":"3490-3502","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition"],"prefix":"10.1158","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-2181","authenticated-orcid":false,"given":"Qi","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5656-8020","authenticated-orcid":false,"given":"Bohan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6199-8263","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-3074","authenticated-orcid":false,"given":"Zixi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6349-3734","authenticated-orcid":false,"given":"Mingming","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1645-3221","authenticated-orcid":false,"given":"Jialu","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-8409","authenticated-orcid":false,"given":"Yuzeshi","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7557-2829","authenticated-orcid":false,"given":"Shan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-2579","authenticated-orcid":false,"given":"Ke","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8101-6159","authenticated-orcid":false,"given":"Yanlin","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7710-5458","authenticated-orcid":false,"given":"Yizeng","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-1986","authenticated-orcid":false,"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5747-5766","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0518-5249","authenticated-orcid":false,"given":"Yang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-4689","authenticated-orcid":false,"given":"Jian","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-8722","authenticated-orcid":false,"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2025091503071062300_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"2025091503071062300_bib2","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025091503071062300_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"2025091503071062300_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025091503071062300_bib5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"De Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091503071062300_bib6","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"2025091503071062300_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2020.09.024","article-title":"Efficacy of PARP inhibition in metastatic castration-resistant prostate cancer is very different with non-BRCA DNA repair alterations: reconstructing prespecified endpoints for cohort B from the phase 3 PROfound trial of olaparib","volume":"79","author":"Stopsack","year":"2021","journal-title":"Eur Urol"},{"key":"2025091503071062300_bib8","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1200\/JCO.20.02246","article-title":"BRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike?","volume":"38","author":"Markowski","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091503071062300_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41571-020-0395-x","article-title":"Olaparib for DNA repair-deficient prostate cancer \u2014 one for all, or all for one?","volume":"17","author":"Antonarakis","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025091503071062300_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2021.03.001","article-title":"Treatment and patient selection for patients with metastatic castration-resistant prostate after progression on docetaxel and abiraterone\/enzalutamide: when to play your CARD and when to do your PARP","volume":"80","author":"Robinson","year":"2021","journal-title":"Eur Urol"},{"key":"2025091503071062300_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nsmb.2096","article-title":"Unraveling the mechanism of BRCA2 in homologous recombination","volume":"18","author":"Holloman","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"2025091503071062300_bib12","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41467-020-15689-9","article-title":"Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1","volume":"11","author":"Ehl\u00e9n","year":"2020","journal-title":"Nat Commun"},{"key":"2025091503071062300_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(21)00272-2","article-title":"BRCA2: a 25-year journey from gene identification to targeted cancer treatment","volume":"22","author":"Grinda","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025091503071062300_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2025091503071062300_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2025091503071062300_bib16","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1093\/nar\/gkw087","article-title":"Targeting BRCA1-and BRCA2-deficient cells with RAD52 small molecule inhibitors","volume":"44","author":"Huang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025091503071062300_bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.chembiol.2021.02.006","article-title":"A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death","volume":"28","author":"Scott","year":"2021","journal-title":"Cell Chem Biol"},{"key":"2025091503071062300_bib18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"key":"2025091503071062300_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.add2187","article-title":"Robust deep learning\u2013based protein sequence design using ProteinMPNN","volume":"378","author":"Dauparas","year":"2022","journal-title":"Science"},{"key":"2025091503071062300_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025091503071062300_bib21","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem Soc Rev"},{"key":"2025091503071062300_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1021\/jacsau.3c00795","article-title":"Development of a double-stapled peptide stabilizing both \u03b1-helix and \u03b2-sheet structures for degrading transcription factor AR-V7","volume":"4","author":"Ma","year":"2024","journal-title":"JACS Au"},{"key":"2025091503071062300_bib23","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1021\/acs.jmedchem.3c01264","article-title":"Discovery of ARD-1676 as a highly potent and orally efficacious AR PROTAC degrader with a broad activity against AR mutants for the treatment of AR+ human prostate cancer","volume":"66","author":"Xiang","year":"2023","journal-title":"J Med Chem"},{"key":"2025091503071062300_bib24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J Med Chem"},{"key":"2025091503071062300_bib25","doi-asserted-by":"crossref","first-page":"10.1200","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025091503071062300_bib26","doi-asserted-by":"crossref","first-page":"e2201859","DOI":"10.1002\/advs.202201859","article-title":"De novo design of an androgen receptor DNA binding domain-targeted peptide PROTAC for prostate cancer therapy","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci"},{"key":"2025091503071062300_bib27","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.1038\/s41467-024-54978-5","article-title":"DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity","volume":"15","author":"Ye","year":"2024","journal-title":"Nat Commun"},{"key":"2025091503071062300_bib28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ccell.2023.05.016","article-title":"Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"2025091503071062300_bib29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","article-title":"Patient-derived xenografts and organoids model therapy response in prostate cancer","volume":"12","author":"Karkampouna","year":"2021","journal-title":"Nat Commun"},{"key":"2025091503071062300_bib30","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nature05175","article-title":"Molecular architecture and assembly of the DDB1\u2013CUL4A ubiquitin ligase machinery","volume":"443","author":"Angers","year":"2006","journal-title":"Nature"},{"key":"2025091503071062300_bib31","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1038\/s41467-023-43174-6","article-title":"Structure of the DDB1-AMBRA1 E3 ligase receptor complex linked to cell cycle regulation","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"2025091503071062300_bib32","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.297.5588.1837","article-title":"BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure","volume":"297","author":"Yang","year":"2002","journal-title":"Science"},{"key":"2025091503071062300_bib33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","article-title":"Rational discovery of molecular glue degraders via scalable chemical profiling","volume":"16","author":"Mayor-Ruiz","year":"2020","journal-title":"Nat Chem Biol"},{"key":"2025091503071062300_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"2025091503071062300_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"2025091503071062300_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/acschembio.3c00487","article-title":"Targeted protein degradation through recruitment of the CUL4 complex adaptor protein DDB1","volume":"19","author":"Meyers","year":"2024","journal-title":"ACS Chem Biol"},{"key":"2025091503071062300_bib37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41598-019-57333-7","article-title":"Synthesis and characterization of selenium nanoparticles-lysozyme nanohybrid system with synergistic antibacterial properties","volume":"10","author":"Vahdati","year":"2020","journal-title":"Sci Rep"},{"key":"2025091503071062300_bib38","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.nantod.2021.101205","article-title":"The recent biological applications of selenium-based nanomaterials","volume":"38","author":"Huang","year":"2021","journal-title":"Nano Today"},{"key":"2025091503071062300_bib39","doi-asserted-by":"crossref","first-page":"105162","DOI":"10.1016\/j.ebiom.2024.105162","article-title":"Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response","volume":"104","author":"Xu","year":"2024","journal-title":"EBioMedicine"},{"key":"2025091503071062300_bib40","doi-asserted-by":"crossref","first-page":"109478","DOI":"10.1016\/j.celrep.2021.109478","article-title":"BRCA2 deficiency reveals that oxidative stress impairs RNaseH1 function to cripple mitochondrial DNA maintenance","volume":"36","author":"Renaudin","year":"2021","journal-title":"Cell Rep"},{"key":"2025091503071062300_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"Xia","year":"2006","journal-title":"Mol Cell"},{"key":"2025091503071062300_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1097-2765(01)00175-7","article-title":"Role of BRCA2 in control of the RAD51 recombination and DNA repair protein","volume":"7","author":"Davies","year":"2001","journal-title":"Mol Cell"},{"key":"2025091503071062300_bib43","doi-asserted-by":"crossref","first-page":"21429","DOI":"10.1074\/jbc.M000961200","article-title":"Nuclear transport of human DDB protein induced by ultraviolet light","volume":"275","author":"Liu","year":"2000","journal-title":"J Biol Chem"},{"key":"2025091503071062300_bib44","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1128\/MCB.00819-06","article-title":"DDB1 maintains genome integrity through regulation of Cdt1","volume":"26","author":"Lovejoy","year":"2006","journal-title":"Mol Cell Biol"},{"key":"2025091503071062300_bib45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41586-024-07196-4","article-title":"Cryo-EM structures of RAD51 assembled on nucleosomes containing a DSB site","volume":"628","author":"Shioi","year":"2024","journal-title":"Nature"},{"key":"2025091503071062300_bib46","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.molcel.2023.06.031","article-title":"Visualization of direct and diffusion-assisted RAD51 nucleation by full-length human BRCA2 protein","volume":"83","author":"Belan","year":"2023","journal-title":"Mol Cell"},{"key":"2025091503071062300_bib47","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41588-023-01557-x","article-title":"Complex synthetic lethality in cancer","volume":"55","author":"Ryan","year":"2023","journal-title":"Nat Genet"},{"key":"2025091503071062300_bib48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"key":"2025091503071062300_bib49","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41565-021-01017-9","article-title":"The ancillary effects of nanoparticles and their implications for nanomedicine","volume":"16","author":"Stater","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"2025091503071062300_bib50","doi-asserted-by":"crossref","first-page":"e1901223","DOI":"10.1002\/adhm.201901223","article-title":"Size-dependent EPR effect of polymeric nanoparticles on tumor targeting","volume":"9","author":"Kang","year":"2020","journal-title":"Adv Healthc Mater"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-24-4096\/3637741\/can-24-4096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/18\/3490\/3647597\/can-24-4096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/85\/18\/3490\/3647597\/can-24-4096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:07:36Z","timestamp":1757920056000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/85\/18\/3490\/764450\/A-Peptide-Based-PROTAC-Degrader-of-BRCA2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":50,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-24-4096","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.30125752","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125740","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125755","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125758","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125746","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125749","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30125737","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8034685","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}